

**Claims Currently in the Case:**

This listing of claims below will replace all prior versions and listings of claims in the application. Insertions are indicated by underscoring. Deletions are indicated by strikethrough typeface or by double brackets.

**Listing of Claims:**

1-84. (Cancelled)

85. (Currently Amended) A method for administration of a substance to a mammal, the method comprising injecting the substance into the dermis of the mammal by bolus administration, wherein improved systemic absorption is produced relative to absorption produced upon injecting the substance subcutaneously by bolus administration and wherein the substance is ~~a growth hormone~~, a low molecular weight heparin or a dopamine receptor agonist.

86. (Cancelled)

87. (Previously presented) The method of claim 85 wherein the substance is a low molecular weight heparin.

88. (Previously presented) The method of claim 85 wherein the substance is a dopamine receptor agonist.

89. (Previously presented) The method of claim 85 wherein the substance is in the form of nanoparticles.

90. (Previously presented) The method of claim 85 wherein the injecting is through at least one hollow needle, by electroporation, or by thermal poration.

91. (Previously presented) The method of claim 90 wherein the injecting is through at least one hollow needle.

92. (Previously presented) The method of claim 91 wherein the at least one hollow needle comprises an array of microneedles.

93. (Cancelled)

94. (Previously presented) The method of claim 85 wherein the substance is administered by repeated bolus injections.

95. (Currently Amended) A method for administration of a substance to a mammal, the method comprising selectively injecting the substance into the dermis of the mammal by bolus administration to obtain systemic absorption of the substance from the dermis, wherein improved systemic absorption is produced relative to absorption produced upon injecting the substance subcutaneously by bolus administration and wherein the substance is ~~a growth hormone~~, a low molecular weight heparin or a dopamine receptor agonist.

96. (Previously presented) The method of claim 95 wherein selectively injecting the substance into the dermis is through at least one hollow needle, by electroporation or by thermal poration.

97. (Previously presented) The method of claim 96 wherein selectively injecting the substance into the dermis is through at least one hollow needle having a length and outlet selected for their suitability for delivering the substance into the dermis to obtain systemic absorption of the substance from the dermis.

98. (Cancelled)

99. (Previously presented) The method of claim 95 wherein the substance is a low molecular weight heparin.

100. (Previously presented) The method of claim 95 wherein the substance is a dopamine receptor agonist.

101. (Previously presented) The method of claim 95 wherein the substance is in the form of nanoparticles

102. (Previously presented) The method of Claim 97 wherein the at least one hollow needle comprises an array of microneedles.

103-104. (Cancelled)

105. (Previously presented) The method of claim 95 wherein the substance is administered by repeated bolus injections.

106. (Currently Amended) A method for administration of a substance to a mammal, the method comprising selectively injecting the substance into the dermis of the mammal by bolus administration, wherein improved systemic absorption of the substance is produced relative to absorption produced upon injecting the substance subcutaneously by bolus administration and wherein the substance is ~~a growth hormone~~, a low molecular weight heparin or a dopamine receptor agonist.

107. (Previously presented) The method of claim 106 wherein selectively injecting the substance into the dermis is through at least one hollow needle, by electroporation or by thermal poration.

108. (Previously presented) The method of claim 107 wherein the method comprises selectively injecting the substance into the dermis through at least one hollow needle having a length and outlet selected for their suitability for delivering the substance into the dermis.

109. (Cancelled)

110. (Previously presented) The method of claim 106 wherein the substance is a low molecular weight heparin.

111. (Previously presented) The method of claim 106 wherein the substance is a dopamine receptor agonist.

112. (Previously presented) The method of claim 106 wherein the substance is in the form of nanoparticles.

113. (Previously presented) The method of claim 107 wherein the at least one hollow needle comprises an array of microneedles.

114-115. (Cancelled)

116. (Previously presented) The method of claim 106 wherein the substance is administered by repeated bolus injections.

117. (Withdrawn) A device for administering to a mammal, a composition which comprises a growth hormone, a low molecular weight heparin or a dopamine receptor agonist, the device being configured to selectively deliver the composition into the dermis to obtain systemic absorption of the composition, wherein the device is an electroporation injection system or a thermal poration injection system.

118. (Withdrawn) A device for administering to a mammal, a composition which comprises a growth hormone, a low molecular weight heparin or a dopamine receptor agonist, the device being configured to selectively deliver the composition into the dermis, wherein systemic absorption of the composition is obtained, and wherein the device is an electroporation injection system or a thermal poration injection system.

119. (Currently Amended) A method for administering a substance to a mammal, the method comprising selectively delivering the substance to the dermis by bolus administration to achieve improved systemic absorption as compared to systemic absorption produced upon bolus subcutaneous administration of the substance at an identical dose, wherein the substance is ~~a growth hormone~~, a low molecular weight heparin or a dopamine receptor agonist.

120. (Cancelled)

121. (Previously presented) The method of claim 119 wherein the substance is a low molecular weight heparin.

122. (Previously presented) The method of claim 119 wherein the substance is a dopamine receptor agonist.

123. (Previously presented) The method of claim 119 wherein the substance is in the form of nanoparticles.

124. (Previously presented) The method of claim 119 wherein the delivering is through a hollow needle, by electroporation, or by thermal poration.

125. (Previously presented) The method of claim 124 wherein the delivering is through at least one hollow needle.

126. (Previously presented) The method of claim 125 wherein the at least one hollow needle comprises an array of microneedles.

127. (Cancelled)

128. (Previously presented) The method of claim 119 wherein the substance is administered by repeated bolus injections.

129. (Currently Amended) A method for administering a substance to a mammal, the method comprising selectively delivering the substance to the dermis by bolus administration, wherein improved systemic absorption is produced as compared to systemic absorption produced upon bolus subcutaneous administration of the substance at an identical dose, and wherein the substance is ~~a growth hormone~~, a low molecular weight heparin or a dopamine receptor agonist.

130. (Cancelled)

131. (Previously presented) The method of claim 129 wherein the substance is a low molecular weight heparin.

132. (Previously presented) The method of claim 129 wherein the substance is a dopamine receptor agonist.

133. (Previously presented) The method of claim 129 wherein the substance is in the form of nanoparticles.

134. (Previously presented) The method of claim 129 wherein the delivering is through a hollow needle, by electroporation, or by thermal poration.

135. (Previously presented) The method of claim 129 wherein the delivering is through at least one hollow needle.

136. (Previously presented) The method of claim 135 wherein the at least one hollow needle comprises an array of microneedles.

137. (Cancelled)

138. (Previously presented) The method of claim 129 wherein the substance is administered by repeated bolus injections.